Inhibition of p38α MAPK rescues cardiomyopathy induced by overexpressed β2-adrenergic receptor, but not β1-adrenergic receptor

Journal of Clinical Investigation

Volumn 117, Issue 5, 2007, Pages 1335-1343

  Peter, Pallavi S ^a   Brady, Jennifer E ^a   Yan, Lin ^a   Chen, Wei ^a   Engelhardt, Stefan ^b   Wang, Yibin ^c   Sadoshima, Junichi ^a   Vatner, Stephen F ^a   Vatner, Dorothy E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 14;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; CARDIOMYOPATHIES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 14; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 34248216911     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29576     Document Type: Article

References (39)

1. Bristow, M.R. 2000. β-adrenergic receptor blockade in chronic heart failure. Circulation. 101:558-569.
2. Du, X.J., et al. 2000. Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. Cardiovasc. Res. 48:448-454.
3. Engelhardt, S., Hein, L., Wiesmann, F., and Lohse, M.J. 1999. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 96:7059-7064.
4. Felker, G.M., and O'Connor, C.M. 2001. Inotropic therapy for heart failure: an evidence-based approach. Am. Heart J. 142:393-401.
5. Iwase, M., et al. 1996. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ. Res. 78:517-524.
6. Liggett, S.B., et al. 2000. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 101:1707-1714.
7. Milano, C.A., et al. 1994. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 264:582-586.
8. Vatner, S.F., Vatner, D.E., and Homcy, C.J. 2000. Beta-adrenergic receptor signaling: an acute compensatory adjustment-inappropriate for the chronic stress of heart failure? Insights from Gsalpha overexpression and other genetically engineered animal models. Circ. Res. 86:502-506.
9. Reiken, S., et al. 2003. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 107:2459-2466.
10. Wehrens, X.H., and Marks, A.R. 2004. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat. Rev. Drug Discov. 3:565-573.
11. Wenzel, S., Muller, C., Piper, H.M., and Schluter, K.D. 2005. p38 MAP-kinase in cultured adult rat ventricular cardiomyocytes: expression and involvement in hypertrophic signalling. Eur. J. Heart Fail. 7:453-460.
12. Karoor, V., et al. 2004. Propranolol prevents enhanced stress signaling in Gs alpha cardiomyopathy: potential mechanism for beta-blockade in heart failure. J. Mol. Cell. Cardiol. 36:305-312.
13. Zheng, M., et al. 2000. Beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes. J. Biol. Chem. 275:40635-40640.
14. Zheng, M., Zhu, W., Han, Q., and Xiao, R.P. 2005. Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol. Ther. 108:257-268.
15. Xiao, R.P., et al. 2003. Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation. 108:1633-1639.
16. Xiao, R.P., et al. 2004. Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol. Sci. 25:358-365.
17. 2+/calmodulin kinase II. J. Clin. Invest. 111:617-625. doi:10.1172/JCI200316326.
18. Morisco, C., Zebrowski, D.C., Vatner, D.E., Vatner, S.F., and Sadoshima, J. 2001. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J. Mol. Cell. Cardiol. 33:561-573.
19. Schafer, M., Frischkopf, K., Taimor, G., Piper, H.M., and Schluter, K.D. 2000. Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am. J. Physiol. Cell Physiol. 279:C495-C503.
20. Zhang, S., et al. 2003. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Invest. 111:833-841. doi:10.1172/JCI200316290.
21. Yamamoto, S., et al. 2003. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest. 111:1463-1474. doi:10.1172/ JCI200317459.
22. Communal, C., Colucci, W.S., and Singh, K. 2000. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. J. Biol. Chem. 275:19395-19400.
23. Communal, C., Singh, K., Sawyer, D.B., and Colucci, W.S. 1999. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 100:2210-2212.
24. Adams, J.W., et al. 1998. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. U. S. A. 95:10140-10145.
25. Baines, C.P., and Molkentin, J.D. 2005. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J. Mol. Cell. Cardiol. 38:47-62.
26. Wang, Y., et al. 1998. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273:2161-2168.
27. Liao, P., et al. 2001. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 98:12283-12288.
28. Xiao, R.P., Ji, X., and Lakatta, E.G. 1995. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 47:322-329.
29. Engelbrecht, A.M., Niesler, C., Page, C., and Lochner, A. 2004. p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes. Basic Res. Cardiol. 99:338-350.
30. Ren, J., Zhang, S., Kovacs, A., Wang, Y., and Muslin, A.J. 2005. Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 38:617-623.
31. Sabri, A., Pak, E., Alcott, S.A., Wilson, B.A., and Steinberg, S.F. 2000. Coupling function of endogenous alpha(1)- and beta-adrenergic receptors in mouse cardiomyocytes. Circ. Res. 86:1047-1053.
32. Braz, J.C., et al. 2003. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Invest. 111:1475-1486. doi:10.1172/JCI200317295.
33. Bristow, M.R., et al. 1986. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ. Res. 59:297-309.
34. Steinberg, S.F. 1999. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ. Res. 85:1101-1111.
35. Foody, J.M., Farrell, M.H., and Krumholz, H.M. 2002. Beta-blocker therapy in heart failure: scientific review. JAMA. 287:883-889.
36. Swedberg, K., Hjalmarson, A., Waagstein, F., and Wallentin, I. 1979. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1:1374-1376.
37. Packer, M. 1998. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog. Cardiovasc. Dis. 41:39-52.
38. sα mouse. J. Clin. Invest. 104:551-558.
39. Okumura, S., et al. 2003. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc. Natl. Acad. Sci. U. S. A. 100:9986-9990.